RxSight, Inc. (NASDAQ: RXST) is a Healthcare company (Medical - Devices) with a market capitalization of $203M. The Maz Rating grades it against the other companies in its sector.
RxSight, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $4.83, RxSight, Inc. trades at 1.7x sales and 0.8x book value. Over the last twelve months it generated about $123M of revenue and a net loss of $54M. It runs a gross margin of 76.1%, an operating margin of -50.4% and a net margin of -43.8%. It shows return on equity of -20.1%, return on invested capital of -23.0% and a free cash flow yield of 9.2%. On the balance sheet: a debt-to-equity ratio of 0.04 and a current ratio of 4.20. Over the past 52 weeks the share price ranged from $4.11 to $13.22, with a beta of 1.19.
RxSight, Inc. does not currently pay a dividend.
12 Wall Street analyst ratings cover the stock: 3 Buy, 7 Hold and 2 Sell, for a Hold consensus. This is the sell side's view, separate from the Maz Rating.
As a medical technology enterprise, RxSight, Inc. (which operated as Calhoun Vision, Inc. until its rebranding in February 2017) specializes in the innovation, manufacturing, and distribution of light-adjustable intraocular lenses (LALs). These advanced lenses are specifically designed for use in cataract surgery, serving patients in both domestic and international markets. The cornerstone of the company's offerings is the RxSight system, a sophisticated solution that enables ophthalmologists to precisely tailor and enhance a patient's visual acuity following cataract removal. An integral part of this system is the RxSight light delivery device, an in-office instrument. This device emits UV light in a carefully controlled pattern to modify the LAL, thereby ensuring optimal visual correction after the surgical procedure. RxSight's primary clientele consists of eye surgeons specializing in cataract treatments. The company was founded in 1997 and its corporate headquarters are situated in Aliso Viejo, California.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
No. As of September 2026, RxSight, Inc. (RXST) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 4.63% / 30% · (Cash+Inv) / Mkt Cap (36m) 114.3% / 30% · Interest income / Revenue 9.46% / 5% | Fail |
| S&P Global | Debt / Mkt Cap (36m) 4.63% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 114.3% / 33% · Receivables / Mkt Cap (36m) 7.63% / 49% · Interest income / Revenue 9.46% / 5% | Fail |
| Dow Jones | Debt / Mkt Cap (24m) 4.63% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 114.3% / 33.33% · Receivables / Mkt Cap (24m) 7.63% / 33.33% · Interest income / Revenue 9.46% / 5% | Fail |
| MSCI | Debt / Avg Assets (4Q) 2.37% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 69.5% / 33.33% · Receivables / Avg Assets (4Q) 10.8% / 33.33% · Interest income / Revenue 9.46% / 5% | Fail |
| FTSE | Debt / Total Assets 3.03% / 33.33% · (Cash+ST Inv) / Total Assets 74.8% / 33.33% · (Cash+Recv) / Total Assets 79.8% / 33.33% · Interest income / Revenue 9.46% / 5% | Fail |
No. As of September 2026, RxSight, Inc. (RXST) is classified as NOT HALAL by Maz Vantage: it fails every published Shariah screening standard it could be measured against (AAOIFI, S&P Global, Dow Jones, MSCI and FTSE).
No. RxSight, Inc. is over the AAOIFI limit on (Cash+Inv) / Mkt Cap (36m) and Interest income / Revenue.
About 9.46% of each dividend: RxSight, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.